Article
News briefing: Merck preps FDA pitch after adding more data on V114; Bristol Myers, Exelixis get qu
Rating:
0.0
Views:
92
Likes:
1
Library:
1
Merck has new data out from two Phase III trials on its pneumococcal conjugate vaccine candidate covering 15 different serotypes. The program, dubbed V114, was tested in the first study in healthy adults aged 50 or older, with patients receiving either the experimental vaccine or the approved Prevnar 13, followed
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value